TMPRSS2-ERG Gene Fusions Induce Prostate Tumorigenesis by Modulating MicroRNA MiR-200c
Overview
Affiliations
Chromosomal translocations that juxtapose the androgen-sensitive transmembrane protease, serine 2 (TMPRSS2) gene promoter to the oncogenic ETS-family transcription factor ERG result in excessive ERG overexpression in approximately 50% of prostate cancer (PCa) patients. Although numerous studies have investigated ERG-downstream genes, such studies have not attempted to examine miRNAs, which however are emerging to be important regulators of cancer. Through bioinformatics analysis of ChIP-Seq ERG data and miRNA expression profiling data we nominated miR-200c as a direct target of ERG. Experimentation of PCa cells with ERG overexpression or knockdown demonstrated that ERG directly repressed miR-200c expression by physically binding to the erythroblast transformation-specific (ETS) motif within its promoter. Consequently, miR-200c was downregulated in ERG-positive PCa, and miR-200c target gene expression was restored. In addition, the expression pattern of miR-200c target genes predicted ERG status in clinical PCa specimens. Furthermore, miR-200c was found to be important in modulating ZEB1 upregulation by ERG. Most importantly, miR-200c reconstitution fully reversed ERG-induced epithelial-to-mesenchymal transition (EMT), cell migration and invasion. Therefore, our study report miR-200c as the first miRNA target of ERG and a critical inhibitor of PCa cell motility. Therapeutic delivery of miR-200c may provide personalized treatment for patients with the molecular subtype of PCa that harbors TMPRSS2-ERG gene fusions.
Lu B, Liu Y, Yao Y, Yang T, Zhang H, Yang X Front Oncol. 2024; 14:1355551.
PMID: 38800374 PMC: 11116611. DOI: 10.3389/fonc.2024.1355551.
Goncharov A, Vashakidze N, Kharaishvili G Biomedicines. 2024; 12(2).
PMID: 38398019 PMC: 10886988. DOI: 10.3390/biomedicines12020418.
Kish E, Choudhry M, Gamallat Y, Buharideen S, D D, Bismar T Int J Mol Sci. 2022; 23(9).
PMID: 35563163 PMC: 9105369. DOI: 10.3390/ijms23094772.
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.
Bahmad H, Demus T, Moubarak M, Daher D, Alvarez Moreno J, Polit F Med Sci (Basel). 2022; 10(1).
PMID: 35225948 PMC: 8883996. DOI: 10.3390/medsci10010015.
Role of Metastasis-Related microRNAs in Prostate Cancer Progression and Treatment.
Oh-Hohenhorst S, Lange T Cancers (Basel). 2021; 13(17).
PMID: 34503302 PMC: 8431208. DOI: 10.3390/cancers13174492.